Mechanism of Action
CRFR2-Mediated Cardioprotection
UCN1 binds CRFR2 on cardiac myocytes with high affinity, activating Gs-coupled cAMP/PKA signaling. This elevates intracellular cAMP, improving contractility (positive inotropy) and activating cardioprotective kinase cascades including PI3K/Akt and ERK1/2. PKA also phosphorylates key calcium handling proteins, improving relaxation (positive lusitropy) without harmful calcium overload.
Vasodilation and Peripheral Hemodynamics
CRFR2 in vascular smooth muscle mediates potent vasodilation through cAMP-dependent relaxation and eNOS activation. UCN1 infusion consistently reduces systemic vascular resistance, afterload, and pulmonary pressure while increasing stroke volume. These hemodynamic effects are particularly beneficial in heart failure where elevated vascular resistance impairs cardiac output.
Ischemia-Reperfusion Protection
UCN1 activates the SAFE (Survivor Activating Factor Enhancement) pathway through STAT3 and the RISK pathway through PI3K/Akt-ERK1/2, both of which converge on preservation of mitochondrial membrane potential and reduction of mitochondrial permeability transition pore opening. This protection significantly reduces infarct size in cardiac ischemia-reperfusion models.
Research Summary
Heart Failure Trials
HumanPhase I/II trials of intravenous UCN1 infusion in chronic heart failure patients showed dose-dependent improvements in cardiac output, stroke volume index, and systemic vascular resistance. UCN1 was well tolerated with a favorable hemodynamic profile distinguishing it from classical inotropes that increase myocardial oxygen demand.
Cardioprotection in Ischemia
AnimalUCN1 administered before or during ischemia-reperfusion reduced infarct size by 40-60% in multiple animal models. Post-conditioning with UCN1 also protected against reperfusion injury when administered at the time of reperfusion, supporting potential use in acute MI intervention.
Skeletal Muscle and Metabolic Effects
AnimalCRFR2 in skeletal muscle mediates UCN1's effects on glucose uptake, mitochondrial biogenesis, and anti-atrophy signaling. UCN1 injection prevented cachexia-related muscle wasting in tumor-bearing mice, expanding interest beyond cardiac applications.
Calculate your Urocortin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Heart failure research | 0.5-10 pmol/kg/min | IV infusion x 30-120 min | Intravenous |
| Cardioprotection model | 1-10 nmol/kg | Single pre- or post-ischemia dose | IV or SC (animal) |
Human trials primarily used IV infusion. Subcutaneous bioavailability in humans is not well characterized.
Interactions
Safety Profile
Intravenous UCN1 was well tolerated in Phase II trials. Flushing, mild hypotension, and increased heart rate were reported at higher doses, consistent with vasodilatory and positive chronotropic actions. No significant arrhythmias or organ toxicity were observed. The short infusion protocols used in trials minimize prolonged exposure concerns.
References
- [1]Vaughan J, et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature. 1995;378:287-292.
- [2]Brar BK, et al. Urocortins do not activate the hypothalamic-pituitary-adrenal axis but do confer cardioprotection. Am J Physiol. 2002.
- [3]Rademaker MT, et al. Hemodynamic, hormonal, and renal effects of urocortin in acute ischemic heart failure. Am J Physiol. 2002.